#United States #Scientific Advisory Board #Wellesley Hills #CureAlz #Alzheimer's Fund

Cure Alzheimer’s Fund Expands Scientific Advisory Board

Cure Alzheimer’s Fund (CureAlz), a prominent nonprofit organization focused on Alzheimer’s disease research, has recently announced the addition of four distinguished experts to its Scientific Advisory Board (SAB). This move aims to enhance the organization’s capacity to develop innovative strategies in the fight against Alzheimer’s disease. The newly appointed members include Dr. Michelle Arkin, Dr. Ronald B. DeMattos, Dr. Donna M. Huryn, and Dr. Kalpana Merchant. Together, they bring a wealth of expertise that will strategically guide CureAlz’s research initiatives.

The SAB is instrumental in shaping the scientific direction and guiding the research investment strategy of CureAlz. Members leverage their extensive backgrounds in translating scientific advances into therapeutic applications, ensuring that the organization’s investments are directed toward the most promising avenues for research into Alzheimer’s prevention, risk reduction, and the acceleration of treatment development. As Meg Smith, CEO of Cure Alzheimer's Fund, stated, the inclusion of these experts provides reassurance that every dollar invested in research has the potential to yield significant breakthroughs in Alzheimer’s care.

Noteworthy Contributions from New Members

Dr. Michelle Arkin serves as a Professor of Pharmaceutical Chemistry at the University of California, San Francisco. Her lab is known for developing innovative methods to target previously deemed